
Lucid Genomics is an AI-driven platform that transforms genomic data into actionable insights for research, drug discovery, and clinical diagnostics. The company offers comprehensive genome analysis, focusing on variant detection, prioritization, and interpretation. With a strong emphasis on precision and scalability, Lucid Genomics aims to empower researchers and clinicians by providing tools that reduce false positives and enhance the accuracy of genetic insights. Their innovative technology integrates multi-omics data, making it a valuable resource in the field of personalized medicine and genetic research.

Lucid Genomics is an AI-driven platform that transforms genomic data into actionable insights for research, drug discovery, and clinical diagnostics. The company offers comprehensive genome analysis, focusing on variant detection, prioritization, and interpretation. With a strong emphasis on precision and scalability, Lucid Genomics aims to empower researchers and clinicians by providing tools that reduce false positives and enhance the accuracy of genetic insights. Their innovative technology integrates multi-omics data, making it a valuable resource in the field of personalized medicine and genetic research.
Headquarters: Berlin, Germany
Founded: 2024
Core product: AI-driven SaaS platform for long-read and multi-omics genome analysis (Lucid Genome Suite)
Focus areas: Structural variants, non-coding regions, variant prioritization & interpretation
Pre-seed raised: €1.3M (announced Sep 2, 2024)
Accurate analysis and interpretation of complex genomic variation (structural variants, repeat regions, non-coding regions) at scale for research, diagnostics and drug discovery.
2024
Biotechnology
€1.3M
Participants included BIF Partners, Another.Vc and the MPF Accelerator program.
Project funding for development of deep-learning structural variant detection.
€270K
Reported as non-dilutive support.
“Caesar Ventures led pre-seed; other participants included BIF Partners, Another.Vc, MPF Accelerator program; received EFRE grant support and MAX!mize non-dilutive support.”